Developer of PharmaCyte Biotech’s COVID-19 Test Explains Why His Test Is So Highly Sensitive, Path to FDA EUA, and Commercialization
20 avr. 2020 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, April 20, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) recently entered into a licensing agreement with Hai Kang Life Corporation (Hai Kang), where Hai Kang granted to...
PharmaCyte Biotech CEO Discusses Navigating Testing and IND Submission During COVID-19 Pandemic
26 mars 2020 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, March 26, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) continues to work with consultants to prepare its Investigational New Drug application (IND). At the same time,...
PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
27 janv. 2020 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical...
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
14 janv. 2020 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
PharmaCyte Biotech Set to Reach Three Major Milestones in 2020
06 janv. 2020 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 06, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech’s (OTCQB: PMCB) shareholders should expect 2020 to be the year that ushers in a host of much-anticipated milestones. This year the...
PharmaCyte Biotech Finalizes Pancreatic Cancer Treatment for U.S. FDA Approval to Begin Clinical Trial
11 déc. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Dec. 11, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a clinical trial product, a clinical trial protocol, including a clinical trial design, a Principal Investigator,...
PharmaCyte Biotech’s “Release Testing” Last Critical Event Before Submission of Investigational New Drug Application
12 nov. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Nov. 12, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can...
PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial
28 oct. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable...
PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product
16 oct. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Oct. 16, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug...
PharmaCyte Biotech's Pancreatic Cancer Therapy Production in Final Days of Key Manufacturing Run
23 sept. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) and its partner, Austrianova, along with the company’s cellular biologist, David Judd, are all more confident than...